| 000 | 01659 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513204358.0 | ||
| 264 | 0 | _c20000503 | |
| 008 | 200005s 0 0 eng d | ||
| 022 | _a0014-5793 | ||
| 024 | 7 |
_a10.1016/s0014-5793(00)01289-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aExner, M | |
| 245 | 0 | 0 |
_aThe salicylate metabolite gentisic acid, but not the parent drug, inhibits glucose autoxidation-mediated atherogenic modification of low density lipoprotein. _h[electronic resource] |
| 260 |
_bFEBS letters _cMar 2000 |
||
| 300 |
_a47-50 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aArteriosclerosis _xprevention & control |
| 650 | 0 | 4 |
_aAspirin _xmetabolism |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aDiabetic Angiopathies _xprevention & control |
| 650 | 0 | 4 |
_aEndothelium, Vascular _xdrug effects |
| 650 | 0 | 4 | _aGentisates |
| 650 | 0 | 4 |
_aGlucose _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxybenzoates _xmetabolism |
| 650 | 0 | 4 |
_aIron Chelating Agents _xmetabolism |
| 650 | 0 | 4 |
_aLipoproteins, LDL _xmetabolism |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aOxidation-Reduction |
| 650 | 0 | 4 |
_aProdrugs _xmetabolism |
| 650 | 0 | 4 |
_aReactive Oxygen Species _xmetabolism |
| 650 | 0 | 4 |
_aSalicylic Acid _xmetabolism |
| 650 | 0 | 4 |
_aThromboplastin _xbiosynthesis |
| 700 | 1 | _aHermann, M | |
| 700 | 1 | _aHofbauer, R | |
| 700 | 1 | _aKapiotis, S | |
| 700 | 1 | _aSpeiser, W | |
| 700 | 1 | _aHeld, I | |
| 700 | 1 | _aSeelos, C | |
| 700 | 1 | _aGmeiner, B M | |
| 773 | 0 |
_tFEBS letters _gvol. 470 _gno. 1 _gp. 47-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0014-5793(00)01289-8 _zAvailable from publisher's website |
| 999 |
_c10676671 _d10676671 |
||